Acute Respiratory Distress Syndrome (ARDS) Market

Market Overview:

The 7 major acute respiratory distress syndrome (ARDS) markets are expected to exhibit a CAGR of 10.1% during 2024-2034.

The acute respiratory distress syndrome (ARDS) market has been comprehensively analyzed in IMARC's new report titled "Acute Respiratory Distress Syndrome (ARDS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute respiratory distress syndrome (ARDS) refers to a severe and life-threatening lung condition characterized by the rapid onset of breathing difficulties and impaired oxygenation of the blood. This ailment typically occurs as a result of an underlying injury or illness, such as pneumonia, sepsis, or trauma, which triggers an inflammatory response in the lungs. Common symptoms of ARDS include severe shortness of breath, rapid and shallow breathing, low oxygen levels in the blood, and the sensation of chest tightness. Individuals suffering from the disorder may also experience confusion and fatigue due to decreased oxygen supply to vital organs. The diagnosis of ARDS involves a combination of clinical evaluation, chest X-rays, and blood gas analysis. A critical criterion for diagnosis is the presence of bilateral opacities on a chest X-ray that cannot be explained by various other conditions. Additionally, arterial blood gas tests reveal low oxygen levels and impaired lung function in patients.

The increasing incidences of several associated risk factors, such as pneumonia, severe infection, inhalation of harmful substances, direct lung injury, chest trauma, drug overdose, pancreatitis, etc., are primarily driving the acute respiratory distress syndrome (ARDS) market. In addition to this, the inflating utilization of effective treatments, including mechanical ventilation, positive end-expiratory pressure (PEEP), and prone positioning, to manage the condition and alleviate breathing difficulty is also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological interventions like corticosteroids and neuromuscular blockers, as well as the exploration of potential drug candidates targeting inflammation and lung injury pathways, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, where genetic and molecular factors are considered to tailor treatment strategies, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation (ECMO) techniques, which provide vital oxygenation and circulation support to the patient's body, thereby enhancing outcomes, is also augmenting the market growth. Furthermore, the ongoing research into innovative therapies, including stem cell-based regenerative approaches and the development of artificial lungs, is expected to drive the acute respiratory distress syndrome (ARDS) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acute respiratory distress syndrome (ARDS) market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acute respiratory distress syndrome (ARDS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute respiratory distress syndrome (ARDS) market in any manner.

Recent Developments:

• In October 2023, GEn1E Lifesciences Inc. announced that it had been awarded a contract by the United States Department of Health and Human Services, the Biomedical Advanced Research and Development Authority (BARDA), to facilitate the development of the company's novel therapy, GEn-1124, for acute respiratory distress syndrome.
• In April 2023, Direct Biologics announced that the U.S. FDA had approved the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to assess the safety and efficacy of ExoFlo in the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS) from any underlying cause.

Key Highlights:

• Every year in the United States, around 190,000 people are diagnosed with ARDS.
• Its incidence rises with age, from 16 cases per 100,000 person-years in those aged 15 to 19 to 306 instances per 100,000 person-years in those aged 75 to 84.
• Twenty-five percent of ARDS cases are originally classed as mild, with 75% being moderate or severe.
• The disease's frequency in trauma patients may be slightly higher in women.
• ARDS is associated with 74,500 deaths in the United States annually.

Drugs:

MultiStem cell therapy is a patented regenerative medicine product under clinical development that has demonstrated the capacity to stimulate tissue repair and healing in various ways, including generating therapeutic factors in response to signals of inflammation and tissue injury. MultiStem therapy's potential for multidimensional therapeutic impact sets it apart from typical biopharmaceutical medicines that focus on a single mechanism of benefit. The therapy is a one-of-a-kind off-the-shelf stem cell product that can be produced on a large scale, stored frozen for years, and injected without tissue matching or immune suppression.

Reparixin is under clinical development by Dompe Farmaceutici for treating acute respiratory distress syndrome. The medication candidate is administered orally in the form of a tablet or intravenous infusion. It operates by targeting the CXC chemokine receptors, CXCR1 and CXCR2.

ExoFlo marks an emerging phase in regenerative health solutions. This new investigational product for COVID-19-associated acute respiratory distress syndrome (ARDS) uses extracellular vesicles isolated from human bone marrow mesenchymal stromal/stem cells (BM-MSCs) to reduce inflammation and facilitate paracrine signaling capable of strengthening the body's defenses and advancing healing processes. Extracellular vesicles produced from BM-MSCs have been shown in studies to reduce inflammation and promote tissue healing in people.
 

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute respiratory distress syndrome (ARDS) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute respiratory distress syndrome (ARDS) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute respiratory distress syndrome (ARDS) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute respiratory distress syndrome (ARDS) market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute respiratory distress syndrome (ARDS) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acute respiratory distress syndrome (ARDS) across the seven major markets?
• What is the size of the acute respiratory distress syndrome (ARDS) patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute respiratory distress syndrome (ARDS)?
• What will be the growth rate of patients across the seven major markets?
   

Acute Respiratory Distress Syndrome (ARDS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute respiratory distress syndrome (ARDS) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute respiratory distress syndrome (ARDS) market?
• What are the key regulatory events related to the acute respiratory distress syndrome (ARDS) market?
• What is the structure of clinical trial landscape by status related to the acute respiratory distress syndrome (ARDS) market?
• What is the structure of clinical trial landscape by phase related to the acute respiratory distress syndrome (ARDS) market?
• What is the structure of clinical trial landscape by route of administration related to the acute respiratory distress syndrome (ARDS) market?